BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19823753)

  • 1. Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells.
    Li L; Liu J; Diao Z; Shu D; Guo P; Shen G
    Mol Biosyst; 2009 Nov; 5(11):1361-8. PubMed ID: 19823753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.
    Guo S; Tschammer N; Mohammed S; Guo P
    Hum Gene Ther; 2005 Sep; 16(9):1097-109. PubMed ID: 16149908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells.
    Liu H; Guo S; Roll R; Li J; Diao Z; Shao N; Riley MR; Cole AM; Robinson JP; Snead NM; Shen G; Guo P
    Cancer Biol Ther; 2007 May; 6(5):697-704. PubMed ID: 17426446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers.
    Tarapore P; Shu Y; Guo P; Ho SM
    Mol Ther; 2011 Feb; 19(2):386-94. PubMed ID: 21063391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells.
    Guo S; Huang F; Guo P
    Gene Ther; 2006 May; 13(10):814-20. PubMed ID: 16482206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells.
    Shu Y; Cinier M; Shu D; Guo P
    Methods; 2011 Jun; 54(2):204-14. PubMed ID: 21320601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach.
    Shu Y; Cinier M; Fox SR; Ben-Johnathan N; Guo P
    Mol Ther; 2011 Jul; 19(7):1304-11. PubMed ID: 21468002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
    Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
    Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene.
    Qiu C; Peng WK; Shi F; Zhang T
    Genet Mol Res; 2012 Sep; 11(3):3236-45. PubMed ID: 23079817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances in Phi29 pRNA biology and its application in drug delivery.
    Ye X; Hemida M; Zhang HM; Hanson P; Ye Q; Yang D
    Wiley Interdiscip Rev RNA; 2012; 3(4):469-81. PubMed ID: 22362726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells.
    Shu Y; Shu D; Haque F; Guo P
    Nat Protoc; 2013 Sep; 8(9):1635-59. PubMed ID: 23928498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabrication of Polyvalent Therapeutic RNA Nanoparticles for Specific Delivery of siRNA, Ribozyme and Drugs to Targeted Cells for Cancer Therapy.
    Shu Y; Shu D; Diao Z; Shen G; Guo P
    IEEE NIH Life Sci Syst Appl Workshop; 2009 May; 2009():9-12. PubMed ID: 21243099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.
    Guo P
    J Nanosci Nanotechnol; 2005 Dec; 5(12):1964-82. PubMed ID: 16430131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs.
    Zhang HM; Su Y; Guo S; Yuan J; Lim T; Liu J; Guo P; Yang D
    Antiviral Res; 2009 Sep; 83(3):307-16. PubMed ID: 19616030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of bacteriophage phi29 DNA packaging motor and its applications in nanotechnology and therapy.
    Lee TJ; Schwartz C; Guo P
    Ann Biomed Eng; 2009 Oct; 37(10):2064-81. PubMed ID: 19495981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells.
    Zhang HZ; Wang Y; Gao P; Lin F; Liu L; Yu B; Ren JH; Zhao H; Wang R
    Cancer Biol Ther; 2006 Nov; 5(11):1457-61. PubMed ID: 17012855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the inter-RNA interaction of bacterial virus phi29 packaging RNA by site-specific photoaffinity cross-linking.
    Garver K; Guo P
    J Biol Chem; 2000 Jan; 275(4):2817-24. PubMed ID: 10644747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The structure, function and recent reseach of pRNA].
    Zhou H; Lu XY; Tian Y; Huang CJ
    Yi Chuan; 2006 Sep; 28(9):1180-4. PubMed ID: 16963432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Tumor-Targeting Nanocarrier System for siRNA Delivery Based on pRNA and Modified Chitosan.
    Li L; Hu X; Zhang M; Ma S; Yu F; Zhao S; Liu N; Wang Z; Wang Y; Guan H; Pan X; Gao Y; Zhang Y; Liu Y; Yang Y; Tang X; Li M; Liu C; Li Z; Mei X
    Mol Ther Nucleic Acids; 2017 Sep; 8():169-183. PubMed ID: 28918019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grouping of ferritin and gold nanoparticles conjugated to pRNA of the phage phi29 DNA-packaging motor.
    Moll WD; Guo P
    J Nanosci Nanotechnol; 2007 Sep; 7(9):3257-67. PubMed ID: 18019159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.